

30 September 2024

## ASX Announcement

### Retirement of Non-Executive Director

PolyNovo Limited (**PolyNovo** or **Company**) advises that Mr Bruce Rathie has retired from his position as Non-Executive Director, effective 30 September 2024.

Mr Rathie was appointed a Director of PolyNovo on 18 February 2010. Mr Rathie has supported the Company throughout its lifecycle from initial research and development to product commercialisation, being taken public, and the Company's subsequent global expansion. Mr. Rathie has also been a well-respected member of the Company's Audit and Risk Committee. The Board of Directors acknowledges Mr Rathie's significant contribution to the Company, thanks him for his service and wishes him the very best for his future endeavours.

Chairman, David Williams said: "Bruce has been the one constant on the PolyNovo Board. He has been there from the start and the rest of us are standing on his shoulders. After 14 years Bruce has selflessly decided to stand aside to make way for new blood and concentrate on his other Board roles. He will be missed but I am confident he will still be available for his sage advice."

This announcement has been authorised by PolyNovo General Counsel & Company Secretary, Lior Harel.

#### About PolyNovo®

PolyNovo is a disruptive ASX 200 medical technology company, based out of Melbourne, Australia. Its products simplify management of acute complex wounds, redefining healing with meaningfully differentiated patient outcomes across multiple wound etiologies. After treating 50,000+ patients across 41 countries, the company is investing for growth via new products, indications, and markets. For more information see [polyново.com](https://polyново.com)

#### About NovoSorb®

NovoSorb BTM is a dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma or burn. NovoSorb is a novel range of bio-resorbable polymers that can be produced in many formats including film, fibre, foam, and coatings. NovoSorb's unique properties provide excellent biocompatibility, control over physical properties, and a programmable bio-resorption profile.